These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation. Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164 [TBL] [Abstract][Full Text] [Related]
3. A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study. Segovia J; Rodríguez-Lambert JL; Crespo-Leiro MG; Almenar L; Roig E; Gómez-Sánchez MA; Lage E; Manito N; Alonso-Pulpón L Transplantation; 2006 Jun; 81(11):1542-8. PubMed ID: 16770243 [TBL] [Abstract][Full Text] [Related]
4. Cytokine-release syndrome: differences between high and low doses of OKT3. Norman DJ; Kimball JA; Barry JM Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420 [No Abstract] [Full Text] [Related]
5. A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients. Stratta RJ; Taylor RJ; Weide LG; Sindhi R; Sudan D; Castaldo P; Cushing KA; Frisbie K; Radio SJ Transplant Proc; 1996 Apr; 28(2):917-8. PubMed ID: 8623461 [No Abstract] [Full Text] [Related]
6. Prevention of OKT3 nephrotoxicity after kidney transplantation. Abramowicz D; De Pauw L; Le Moine A; Sermon F; Surquin M; Doutrelepont JM; Ickx B; Depierreux M; Vanherweghem JL; Kinnaert P; Goldman M; Vereerstraeten P Kidney Int Suppl; 1996 Jan; 53():S39-43. PubMed ID: 8770989 [TBL] [Abstract][Full Text] [Related]
7. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study. Vincenti F; Danovitch GM; Neylan JF; Steiner RW; Everson MP; Gaston RS Transplantation; 1996 Feb; 61(4):573-7. PubMed ID: 8610383 [TBL] [Abstract][Full Text] [Related]
8. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Cantarovich M; Latter DA; Loertscher R Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721 [TBL] [Abstract][Full Text] [Related]
10. Treatment of steroid resistant acute rejection after renal transplantation. Oh CK; Kim YS; Kim MS; Kim SI; Park K Transplant Proc; 1996 Jun; 28(3):1453-4. PubMed ID: 8658737 [No Abstract] [Full Text] [Related]
11. Administration of OKT3 as a two-hour infusion does not attenuate first-dose side effects. Kandaswamy R; Kamps M; Matas AJ Transplantation; 1999 Sep; 68(5):709-10. PubMed ID: 10507495 [No Abstract] [Full Text] [Related]
12. HaNDL syndrome after "benign" OKT3-induced meningitis. Thomas MC; Walker R; Wright A Transplantation; 1999 May; 67(10):1384-5. PubMed ID: 10360598 [No Abstract] [Full Text] [Related]
13. Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3. Agarwal RK; Ostaszewski ML; Feld LG; Springate JE; Moxey-Mims MM; O'Neil KM Transplant Proc; 1993 Apr; 25(2):2143-4. PubMed ID: 8470295 [No Abstract] [Full Text] [Related]
14. Two low-dose OKT3 induction regimens following renal transplantation--clinical experience at a single center. Oh HK; Provenzano R; Tayeb J; Satmary N; Jones B Clin Transplant; 1998 Aug; 12(4):343-7. PubMed ID: 9686329 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy of OKT3 for steroid-resistant acute rejection in renal transplant patients. Kumano K; Irie A; Mashimo S; Endo T; Koshiba K Transplant Proc; 1996 Jun; 28(3):1354-5. PubMed ID: 8658691 [No Abstract] [Full Text] [Related]
16. Very early meningoencephalopathy associated with the intraoperative use of OKT3 in renal retransplant. Assmann JB; Fontana V; Pansard HM; Ferreira MB; Bianchin MM Arq Neuropsiquiatr; 2008 Sep; 66(3B):747-8. PubMed ID: 18949276 [No Abstract] [Full Text] [Related]
17. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy. Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735 [No Abstract] [Full Text] [Related]
18. Human donor bone marrow cells can enhance hyporeactivity in renal transplantation using maintenance FK 506 and OKT3 induction therapy. Ciancio G; Carreno M; Mathew J; Ricordi C; Garcia R; Karatzas T; Fuller L; Cirocco R; Burke G; Webb M; Nery J; Tzakis A; Roth D; Esquenazi V; Miller J Transplant Proc; 1996 Apr; 28(2):943-4. PubMed ID: 8623473 [No Abstract] [Full Text] [Related]
19. Case 6: benefits and risks of OKT3 treatment in renal transplantation. First MR Transplantation; 2001 Sep; 72(6):1177-8. PubMed ID: 11584824 [No Abstract] [Full Text] [Related]
20. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity. Vasquez EM; Fabrega AJ; Pollak R Transplant Proc; 1995 Feb; 27(1):873-4. PubMed ID: 7879215 [No Abstract] [Full Text] [Related] [Next] [New Search]